Pharmacist Interventions to Improve Specialty Medication Adherence: Study Protocol for a Randomized Controlled Trial
Amanda M Kibbons, Megan Peter, Josh DeClercq, Leena Choi, Jacob Bell, Jacob Jolly, Elizabeth Cherry, Bassel Alhashemi, Nisha B Shah, Autumn D Zuckerman, Amanda M Kibbons, Megan Peter, Josh DeClercq, Leena Choi, Jacob Bell, Jacob Jolly, Elizabeth Cherry, Bassel Alhashemi, Nisha B Shah, Autumn D Zuckerman
Abstract
Background: The effectiveness of specialty medications in complicated clinical conditions depends on adherence to therapy. However, specialty medications pose unique barriers to adherence.
Objective: This study aims to determine whether pharmacist interventions improve specialty medication adherence.
Methods: This is a single-center, pragmatic, randomized controlled trial ongoing since 10 May 2019 at an integrated health system specialty pharmacy. This study evaluates usual care compared with usual care plus patient-tailored adherence interventions. Study design and procedures were informed by focus groups with patients and specialty pharmacists. Patients at Vanderbilt Specialty Pharmacy with a proportion of days covered (PDC) < 90% in the previous 4 months are identified by a daily query of the electronic pharmacy database. A pharmacist reviews these patients' electronic health records to identify and exclude ineligible patients. Eligible patients are randomized evenly to the control or intervention arm and stratified by historical clinic nonadherence rates. Patients randomized to the intervention arm undergo a baseline assessment to clarify reasons for nonadherence and subsequently receive patient-tailored interventions based on their specific reasons. Interventions and follow-up are provided at the discretion of the intervening pharmacist. The primary outcome is PDC calculated at 8 months post-enrollment. Enrollment of 438 participants will provide 90% power to detect a 5% difference in PDC between the two arms within each nonadherence risk stratum.
Discussion: This trial will evaluate the effect of patient-tailored interventions on specialty medication adherence and will inform how often and why patients are misidentified as nonadherent.
Registration: The trial was deemed a quality improvement initiative by the Vanderbilt University Institutional Review Board. It was registered in ClinicalTrials.gov (NCT03709277) on 17 October 2018.
Conflict of interest statement
Amanda Kibbons, Megan Peter, DeClercq, Leena Choi, Jacob Bell, Jacob Jolly, Elizabeth Cherry, Bassel Alhashemi, Nisha Shah, and Autumn Zuckerman have no conflicts of interest that are directly relevant to the content of this article.
Figures
References
- Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug-related morbidity and mortality. Ann Pharmacother. 2018;52(9):829–837. doi: 10.1177/1060028018765159.
- Express Scripts 2019 Drug Trend report: Accessed 3 Dec 20
- Pascual-Ramos V, Contreras-Yanez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11(1):R26. doi: 10.1186/ar2620.
- Carrat F, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–1464. doi: 10.1016/s0140-6736(18)32111-1.
- Hoy SM. Elexacaftor/Ivacaftor/Tezacaftor: first approval. Drugs. 2019;79(18):2001–2007. doi: 10.1007/s40265-019-01233-7.
- Roubille C, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the canadian dermatology-rheumatology comorbidity initiative. J Rheumatol. 2015;42(10):1767–1780. doi: 10.3899/jrheum.141112.
- Moss BP, Rensel MR, Hersh CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017;14(4):999–1017. doi: 10.1007/s13311-017-0563-6.
- Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med. 2017;46(6 Pt 2):e125–e138. doi: 10.1016/j.lpm.2017.05.011.
- Duhig AM, Saha S, Smith S, Kaufman S, Hughes J. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. J Manag Care Spec Pharm. 2018;24(5):410–415. doi: 10.18553/jmcp.2017.16326.
- Canfield SL, et al. Navigating the wild west of medication adherence reporting in specialty pharmacy. J Manag Care Spec Pharm. 2019;25(10):1073–1077. doi: 10.18553/jmcp.2019.25.10.1073.
- Paolella D, Cherry E, Jolly JA, DeClercq J, Choi L, Zuckerman A. Closing the gap: identifying rates and reasons for nonadherence in a specialty population. J Manag Care Spec Pharm. 2019;25(11):1282–1288. doi: 10.18553/jmcp.2019.25.11.1282.
- Vrijens B, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi: 10.1111/j.1365-2125.2012.04167.x.
- Mohler R, Kopke S, Meyer G. Criteria for reporting the development and evaluation of complex interventions in healthcare: revised guideline (CReDECI 2. Trials. 2015;16:204. doi: 10.1186/s13063-015-0709-y.
- P. Q. Alliance, "PQA’s Specialty Core Measure’s Set," ed.
- Govani SM, et al. Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases. Am J Gastroenterol. 2018;113(2):276–282. doi: 10.1038/ajg.2017.438.
- Harris PA, Scott KW, Lebo L, Hassan N, Lightner C, Pulley J. ResearchMatch: a national registry to recruit volunteers for clinical research. Acad Med. 2012;87(1):66–73. doi: 10.1097/ACM.0b013e31823ab7d2.
- Harris PA, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.
- Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36–44. doi: 10.1345/aph.1K671.
- Nau DP (2012) Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Pharm Qual Alliacne 1–3.
- Garcia-Sempere A, Hurtado I, Sanfelix-Genoves J, Rodriguez-Bernal C, Peiro S, Sanfelix-Gimeno G. Improving the accuracy of medication adherence measures using linked prescription and dispensation data: findings from the ESOSVAL cohort of patients treated with osteoporosis drugs. Curr Med Res Opin. 2019;35(9):1535–1544. doi: 10.1080/03007995.2019.1601944.
- Forbes CA, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin. 2018;34(9):1613–1625. doi: 10.1080/03007995.2018.1477747.
- DeClerq J, Choi L. Statistical considerations for medication adherence research. Curr Med Res Opin. 2020;36:1549–1557. doi: 10.1080/03007995.2020.1793312.
- O. World Health, "Adherence to long-term therapies: evidence for action/[edited by Eduardo Sabaté]," ed. Geneva: World Health Organization, 2003.
- Gellad W, Grenard J, McGlynn E. A review of barriers to medication adherence: a framework for driving policy options. RAND Corportation, 2009.
- Bagwell A, Kelley T, Carver A, Lee JB, Newman B. Advancing patient care through specialty pharmacy services in an academic health system. J Manag Care Spec Pharm. 2017;23(8):815–820. doi: 10.18553/jmcp.2017.23.8.815.
- Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269–286. doi: 10.2147/tcrm.s1458.
- Weiss BD. Quick assessment of literacy in primary care: the newest vital sign. Ann Fam Med. 2005;3(6):514–522. doi: 10.1370/afm.405.
- Tamargo C, Sando K, Prados Y, Cowart K. Change in proportion of days covered for statins following implementation of a pharmacy student adherence outreach program. J Manag Care Special Pharm. 2019;25(5):588–592. doi: 10.18553/jmcp.2019.25.5.588.
- Nieuwlaat R, et al. Interventions enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. doi: 10.1002/14651858.CD000011.pub4.
- Mann A, Esse TW, Serna O, Castel LD, Abughosh SM. Effectiveness of miled letters to improve medication adherence among medicare advantage plan participants with chronic conditions. Patient Prefer Adher. 2019;13:37–46. doi: 10.2147/PPA.S185848.
- Mishra SI, Gioia D, Childress S, Barnet B, Webster RL. Adherence to medication regimens among low-income patients with multiple comorbid chronic conditions. Health Soc Work. 2011;36(4):249–258. doi: 10.1093/hsw/36.4.249.
- Márquez Contreras E, Vegazo García O, Martel Claros N, Gil Guillén V, de la Figuera von Wichmann M, Casado Martínez JJ, Fernández R. Efficacy of telephone and mail intervention in patient compliance with antihypertensive drugs in hypertension. ETECUM-HTA study. Blood Press. 2009;14(3):151–158. doi: 10.1080/08037050510008977.
- Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002;53(2):163–171. doi: 10.1046/j.0306-5251.2001.01531.x.
Source: PubMed